{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-036194","form_type":"8-K","ticker":"BAX","cik":"0000010456","company_name":"BAXTER INTERNATIONAL INC","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.014110+00:00","generated_at":"2026-06-08T23:12:02.801565+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Baxter Q3 2023 adjusted EPS $0.68 from continuing ops beats guidance; completes $4.25B BPS divestiture","bullets":["Q3 revenue from continuing ops $3.71B (+3% reported, +2% CC), ahead of company guidance.","GAAP EPS from continuing ops $0.09; adjusted EPS $0.68, exceeded prior guidance.","Completed BioPharma Solutions divestiture for $4.25B; cash proceeds $3.96B; gain $2.89B; debt repayment use.","Kidney Care spinoff on track to close by July 2024.","FY 2023 adjusted EPS guidance $2.57-$2.60; Q4 2023 adjusted EPS guidance $0.85-$0.88."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-036194","json":"https://secwatch.observer/filing/0001628280-23-036194.json","markdown":"https://secwatch.observer/filing/0001628280-23-036194.md","text":"https://secwatch.observer/filing/0001628280-23-036194.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/10456/000162828023036194/0001628280-23-036194-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/10456/000162828023036194/bax-20231102.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T23:12:02.801565+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3fd4d6d8a1ec8b94ed4ce23b311e55a448bd4a85","claim":"BAXTER INTERNATIONAL INC reported third quarter 2023 results: revenue $3.71 billion, net income $2.51 billion, EPS $4.93 per diluted share.","evidence_excerpt":"BAXTER REPORTS THIRD-QUARTER 2023 RESULTS • Third-quarter revenue from continuing operations of $3.71 billion increased 3% on a reported basis and 2% on a constant currency basis, ahead of the company’s previously issued guidance 1 • Third-quarter U.S. GAAP earnings per share (EPS) from continuing operations of $0.09; adjusted EPS from continuing operations of $0.68 exceeded guidance • Third-quarter U.S. GAAP EPS in the aggregate (including discontinued operations) totaled $4.93; adjusted EPS in the aggregate (including discontinued operations) of $0.82 exceeded guidance","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/10456/000162828023036194/0001628280-23-036194-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter 2023"},{"label":"Revenue","value":"$3.71 billion"},{"label":"Net income","value":"$2.51 billion"},{"label":"EPS","value":"$4.93 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}